Opinion|Videos|January 7, 2025
Managing Disease Progression in MS: Changing Treatments and Clinician Advice
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Disease progression on high-efficacy therapy necessitates strategic treatment modification, considering both within-class switches and different mechanisms of action based on patient response.
- Switching within the same class may be appropriate for partial response or tolerability issues, while a different mechanism is advised for complete lack of efficacy.
Panelists discuss how in multiple sclerosis (MS) treatment, clinicians must strategically evaluate disease progression, considering within-class or mechanism-of-action switches. Comprehensive monitoring, personalized approaches, and proactive management are crucial for optimizing patient outcomes and minimizing long-term neurological disability.
Advertisement
Video content above is prompted by the following:
- In cases where a patient continues to show disease progression on a high-efficacy therapy, what is your approach to changing treatment? When would you recommend switching within class and when to a different mechanism of action?
- In closing, what advice would you like to share with clinicians who are taking care of patients with MS?
Advertisement
Related to this article
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
A published protocol outlines the randomized, open-label EPOCH trial testing whether cilostazol accelerates hematoma resorption and improves recovery after intracerebral hemorrhage.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]
In honor of Muscular Dystrophy Awareness Month, held annually in September, NeurologyLive® looks back at the decade-long expansion of the DMD treatment landscape and the data that supports each approval.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
4
Episode 175: Advancing the Ways of Treating Cluster Headache
5